Pentixapharm Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
80
- Stock Symbol
-
PTP
- Investments
-
1
- Share Price
-
$1.96
- (As of Friday Closing)
Pentixapharm General Information
Description
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
Contact Information
Website
www.pentixapharm.comCorporate Office
- Robert Rossle Street 10
- 13125 Berlin
- Germany
Corporate Office
- Robert Rossle Street 10
- 13125 Berlin
- Germany
Pentixapharm Timeline
Pentixapharm Stock Performance
As of 20-Nov-2026, Pentixapharm’s stock price is $1.96. Its current market cap is $70.3M with 35.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.96 | $1.96 | $1.46 - $4.14 | $70.3M | 35.8M | 235.60 | -$0.58 |
Pentixapharm Financials Summary
As of 30-Sep-2026, Pentixapharm has a trailing 12-month revenue of $16.3K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (3,049) | 33,568 | 61,489 | |
| Revenue | 16 | 105 | 128 | 26 |
| EBITDA | (14,980) | (18,195) | 2,242 | (6,508) |
| Net Income | (16,050) | (18,625) | (13,897) | (8,266) |
| Total Assets | 8,425 | 49,168 | 71,075 | 81,134 |
| Total Debt | 0 | 0 | 0 | 0 |
Pentixapharm Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pentixapharm Patents
Pentixapharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026130747-A1 | Antibodies against cd24 | Pending | 19-Dec-2024 | ||
| WO-2026082698-A1 | Conjugates of modified antibody formats | Pending | 14-Oct-2024 | ||
| AU-2025235097-A1 | Improved formulation for radiopharmaceutical compounds | Pending | 15-Mar-2024 | ||
| WO-2025191100-A1 | Improved formulation for radiopharmaceutical compounds | Pending | 15-Mar-2024 | ||
| AU-2024402617-A1 | Antibodies against cd24 | Pending | 19-Dec-2023 | C07K16/2896 |
Pentixapharm Signals
Pentixapharm Acquisitions (1)
Pentixapharm’s most recent deal was a Merger/Acquisition with Glycotope for . The deal was made on 03-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Glycotope | 03-Jul-2024 | Merger/Acquisition | Drug Discovery |
Pentixapharm ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
47.06 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Pentixapharm Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Glycotope | Berlin, Germany | 2000 |
Pentixapharm FAQs
-
When was Pentixapharm founded?
Pentixapharm was founded in 2019.
-
Where is Pentixapharm headquartered?
Pentixapharm is headquartered in Berlin, Germany.
-
What is the size of Pentixapharm?
Pentixapharm has 80 total employees.
-
What industry is Pentixapharm in?
Pentixapharm’s primary industry is Drug Discovery.
-
Is Pentixapharm a private or public company?
Pentixapharm is a Public company.
-
What is Pentixapharm’s stock symbol?
The ticker symbol for Pentixapharm is PTP.
-
What is the current stock price of Pentixapharm?
As of 20-Nov-2026 the stock price of Pentixapharm is $1.96.
-
What is the current market cap of Pentixapharm?
The current market capitalization of Pentixapharm is $70.3M.
-
What is Pentixapharm’s current revenue?
The trailing twelve month revenue for Pentixapharm is $16.3K.
-
What is Pentixapharm’s annual earnings per share (EPS)?
Pentixapharm’s EPS for 12 months was -$0.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process